Signals, Powered By EquityPandit
Sanofi-Synthelabo India has launched two diabetes drugs – Lyxumia and Zemiglo to lower blood sugar levels.
Sanofi-Synthelabo (India) Pvt Ltd has said in a statement that while Lyxumia is a once daily, non-insulin injectable drug, Zemiglo is a once daily, oral tablets.
N Rajaram, Sanofi India Pharmaceutical Operations Country Head & General Manager has said that ” The launch of two additions to Sanofi India portfolio Lyxumia and Zemiglo, is our step forward in developing new solutions for people with type 2 diabetes.”
He further said that it is also a testament to Sanofi India’s commitment to help address the current treatment gaps in the country.
